213 related articles for article (PubMed ID: 28704328)
1. Randomized, Controlled Trial of Dexamethasone Versus Dexamethasone Plus Hydrocortisone as Prophylaxis for Hypersensitivity Reactions Due to Paclitaxel Treatment for Gynecologic Cancer.
Jeerakornpassawat D; Suprasert P
Int J Gynecol Cancer; 2017 Oct; 27(8):1794-1801. PubMed ID: 28704328
[TBL] [Abstract][Full Text] [Related]
2. Preliminary experience with a modified premedication protocol that included intravenous diphenhydramine and calcium bromide for the prophylaxis of paclitaxel-related hypersensitivity reactions.
Sasada S; Hirashima T; Nakamura Y; Takimoto T; Furukawa M; Kobayashi M; Nitta T; Matsui K; Kawase I
Int J Clin Oncol; 2007 Aug; 12(4):274-8. PubMed ID: 17701006
[TBL] [Abstract][Full Text] [Related]
3. Prophylaxis for paclitaxel hypersensitivity reactions.
Kintzel PE
Ann Pharmacother; 2001 Sep; 35(9):1114-7. PubMed ID: 11573863
[TBL] [Abstract][Full Text] [Related]
4. Is a low dose of dexamethasone sufficient to prevent paclitaxel-related hypersensitivity reactions? A retrospective study in patients with gynecologic malignancy.
Xiao D; Yang Z; Shi Y; Yang W; Zhang Y
Expert Rev Clin Pharmacol; 2024; 17(5-6):525-532. PubMed ID: 38652518
[TBL] [Abstract][Full Text] [Related]
5. Incidence of infusion hypersensitivity reaction after withholding dexamethasone premedication in early breast cancer patients not experiencing two previous cycles of infusion hypersensitivity reaction for weekly paclitaxel chemotherapy.
Parinyanitikul N; Tanpipattanakul W; Poovorawan N; Rattananupong T; Laoitthi P; Sithidetphaiboon P; Thanasanvimon S; Sriuranpong V
Support Care Cancer; 2018 Jul; 26(7):2471-2477. PubMed ID: 29435713
[TBL] [Abstract][Full Text] [Related]
6. Intravenous versus oral dexamethasone premedication in preventing Paclitaxel infusion hypersensitivity reactions in gynecological malignancies.
O'Cathail SM; Shaboodien R; Mahmoud S; Carty K; O'Sullivan P; Blagden S; Gabra H; Whear S; Kwon JS; Agarwal R
Int J Gynecol Cancer; 2013 Sep; 23(7):1318-25. PubMed ID: 23907557
[TBL] [Abstract][Full Text] [Related]
7. Premedication strategy for weekly paclitaxel.
Quock J; Dea G; Tanaka M; Gandara D; Lara P; Lau D
Cancer Invest; 2002; 20(5-6):666-72. PubMed ID: 12197222
[TBL] [Abstract][Full Text] [Related]
8. Single-dose dexamethasone paclitaxel premedication.
Micha JP; Rettenmaier MA; Dillman R; Fraser P; Birk C; Brown JV
Gynecol Oncol; 1998 May; 69(2):122-4. PubMed ID: 9600818
[TBL] [Abstract][Full Text] [Related]
9. [Paclitaxel hypersensitivity reactions in patients with advanced ovarian carcinoma].
Kobierski J; Majdak E; Mielcarek P; Emerich J
Ginekol Pol; 2002 Nov; 73(11):1015-20. PubMed ID: 12722392
[TBL] [Abstract][Full Text] [Related]
10. Cross-sensitivity between taxanes in patients with breast cancer.
Sánchez-Muñoz A; Jiménez B; García-Tapiador A; Romero-García G; Medina L; Navarro V; González-Sánchez LA; Alba E
Clin Transl Oncol; 2011 Dec; 13(12):904-6. PubMed ID: 22126735
[TBL] [Abstract][Full Text] [Related]
11. The feasibility of dexamethasone omission in weekly paclitaxel treatment for breast cancer patients.
de Castro Baccarin AL; Irene MN; de Iracema Gomes Cubero D; Luz AS; Castro SN; Sordi R; Móz LES; Del Giglio A
Support Care Cancer; 2019 Mar; 27(3):927-931. PubMed ID: 30069696
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of the effects of oral and intravenous dexamethasone premedication in the prevention of paclitaxel-induced allergic reactions.
Chen FC; Wang LH; Zheng XY; Zhang XM; Zhang J; Li LJ
Oncotarget; 2017 Mar; 8(12):19236-19243. PubMed ID: 27911278
[TBL] [Abstract][Full Text] [Related]
13. Intravenous versus oral dexamethasone for prophylaxis of paclitaxel-associated hypersensitivity reaction in patients with primary ovarian, fallopian tube and peritoneal cancer: A double-blind randomized controlled trial.
Yanaranop M; Chaithongwongwatthana S
Asia Pac J Clin Oncol; 2016 Sep; 12(3):289-99. PubMed ID: 27098551
[TBL] [Abstract][Full Text] [Related]
14. Tapering and discontinuation of glucocorticoid prophylaxis during prolonged weekly to biweekly paclitaxel administration.
Braverman AS; Rao S; Salvatti ME; Adamson B; McManus M; Pierre S
Chemotherapy; 2005 May; 51(2-3):116-9. PubMed ID: 15886470
[TBL] [Abstract][Full Text] [Related]
15. An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions.
Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
J Cancer Res Clin Oncol; 1999 Jul; 125(7):427-9. PubMed ID: 10394964
[TBL] [Abstract][Full Text] [Related]
16. Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction.
Berger MJ; Vargo C; Vincent M; Shaver K; Phillips G; Layman R; Macrae E; Mrozek E; Ramaswamy B; Wesolowski R; Shapiro CL; Lustberg MB
Support Care Cancer; 2015 Jul; 23(7):2019-24. PubMed ID: 25519756
[TBL] [Abstract][Full Text] [Related]
17. Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments.
Feldweg AM; Lee CW; Matulonis UA; Castells M
Gynecol Oncol; 2005 Mar; 96(3):824-9. PubMed ID: 15721432
[TBL] [Abstract][Full Text] [Related]
18. Dose reduction of steroid premedication for paclitaxel: no increase of hypersensitivity reactions.
Köppler H; Heymanns J; Weide R
Onkologie; 2001 Jun; 24(3):283-5. PubMed ID: 11455223
[TBL] [Abstract][Full Text] [Related]
19. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies.
Robinson JB; Singh D; Bodurka-Bevers DC; Wharton JT; Gershenson DM; Wolf JK
Gynecol Oncol; 2001 Sep; 82(3):550-8. PubMed ID: 11520154
[TBL] [Abstract][Full Text] [Related]
20. Prophylactic effect of pemirolast, an antiallergic agent, against hypersensitivity reactions to paclitaxel in patients with ovarian cancer.
Yahata H; Saito M; Sendo T; Itoh Y; Uchida M; Hirakawa T; Nakano H; Oishi R
Int J Cancer; 2006 May; 118(10):2636-8. PubMed ID: 16353140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
